Longevity Science in March 2026 — Progress and Problems
From a vital aging research database that risks disappearing for lack of funding, to promising animal experiments with plasma exchange and thyroid intervention — March 2026 offered a wide range of developments…
Lifespan.io’s monthly roundup functions as a useful barometer for where the longevity field actually stands — not as a victory lap, but as a working inventory. What got published, what was replicated, what is at stake. March 2026 shows a field simultaneously grappling with infrastructure vulnerabilities and genuine biological advances.
On the infrastructure side: João Pedro de Magalhães, one of the most recognized figures in aging genetics, has launched a fundraising campaign to keep the Human Ageing Genomic Resources database running. The database draws over 200,000 visitors per year and has accumulated more than 1,000 scientific citations — it functions as basic tooling for researchers worldwide. That a resource of this scale depends on public donations reveals something uncomfortable about how fragile the funding base for aging research remains, despite growing public interest in the field.
Experiments worth watching
On the scientific side, several animal studies stood out. Researchers reported progress with young plasma infusions in older animals — an approach that has been investigated for years but still lacks clear mechanistic understanding. New results also emerged on thyroid hormone and aging, where treatment in mice showed effects on metabolic markers associated with biological age.
Also notable: an increasing number of studies now use biological clocks — tools that estimate an organism’s biological age based on DNA methylation patterns, independent of chronological age. This makes cross-study comparisons more precise. But it also raises a persistent question: biological clocks measure a correlate of aging, not aging itself. Whether an intervention that turns back the clock actually leads to better health or longer lifespan in practice remains unresolved.
The translation problem persists
The most fundamental challenge in longevity research is unchanged. The vast majority of promising results come from mice or other model organisms. Translating findings to humans is difficult, expensive, and slow. Clinical trials targeting aging are rare, partly because aging is not recognized as a disease — and therefore not an official regulatory target for drug approval.
The field is nonetheless growing. Publications in aging biology have multiplied over the past decade. Venture capital investment in longevity companies hit record levels in 2024 and 2025. But publications and investment are not guarantees that breakthroughs will reach actual people. March 2026 confirms both sides of that story.